The ABCs of antiphospholipid syndrome

Ayşe Bahar Keleşoğlu Dinçer; Doruk Erkan

doi:10.46497/ArchRheumatol.2023.41875

The ABCs of antiphospholipid syndrome

Arch Rheumatol. 2023 Jun 5;38(2):163-173. doi: 10.46497/ArchRheumatol.2023.41875. eCollection 2023 Jun.

Authors

Ayşe Bahar Keleşoğlu Dinçer^{1

2}, Doruk Erkan³

Affiliations

¹ Division of Rheumatology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Türkiye.
² Hospital for Special Surgery, New York, NY, USA.
³ Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, and Weill Cornell Medicine, New York, NY, USA.

Abstract

Antiphospholipid syndrome (APS) is a thromboinflammatory syndrome characterized by thrombotic, microvascular, obstetric, or non-thrombotic events in the setting of persistent antiphospholipid antibodies (aPL), namely anticardiolipin antibody (aCL), anti-β2 glycoprotein-I antibody (aβ2GPI), and lupus anticoagulant (LA). The diagnosis of APS requires careful assessment of the aPL profile, the clinical phenotype, and additional risk factors. The standard management of aPL-related thrombosis is anticoagulation, which is not effective for microvascular and non-thrombotic events. In parallel to our improved understanding of aPL-related mechanisms, the role of immunosuppression has been increasingly investigated. In this review, we summarize the basic concepts and future perspectives in APS.

Keywords: Antiphospholipid antibody; antiphospholipid syndrome; thrombosis..

Publication types

Review